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Abstract
Background: The EQ-5D is a generic questionnaire providing a preference-based index score applicable to
cost-utility analysis. This is the first study to validate the EQ-5D in patients with somatoform disorders.
Methods: Data of the EQ-5D descriptive system, the British and the German EQ-5D index and the EQ Visual
Analogue Scale, the Patient Health Questionnaire 15, the Patient Health Questionnaire 9, the Whiteley Index 7 and
the Short Form 36 were collected from 294 patients at baseline, 244 at 6 months and 256 at 12 months after
baseline.
The discriminative ability of the EQ-5D was evaluated by comparison with a general population sample and by the
ability to distinguish between different symptom severities. Convergent validity was analysed by assessing
associations between the EQ-5D and the other instruments. Responsiveness was evaluated by analysing the effects
on scores between two measurements in groups of patients reporting worse, same or better health. The Bonferroni
correction was employed.
Results: For all items of the EQ-5D except ‘self-care’, patients with somatoform disorders reported more problems
than the general population. The EQ-5D showed discriminative ability in patients with different symptom severities.
For nearly all reference instruments there were significant differences in mean scores between respondents with
and without problems in the various EQ-5D items and strong correlations with the EQ Visual Analogue Scale and
the EQ-5D index scores. Evidence for the responsiveness of the EQ-5D could only be found for patients with better
health; effects were medium at the utmost.
Conclusions: The EQ-5D showed a considerable validity and a limited responsiveness in patients with somatoform
disorders.
Trial registration: Current Controlled Trials ISRCTN55280791
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Background
According to the Food and Drug Administration (FDA)
Guidance document concerning patient-reported out-
comes, the application of an existing patient-reported in-
strument to a new population requires a revalidation of
the instrument in question [1]. The EQ-5D is a prefer-
ence-based, generic index instrument measuring health
related quality of life (HRQOL). Preference-based index
scores are adopted in the calculation of quality adjusted
life years (QALY) and hence possess pivotal relevance in
the field of economic evaluation [2,3]. The EQ-5D is the
most frequently used instrument in the calculation of
QALY [4]. The psychometric properties of the EQ-5D
have been demonstrated in populations with different dis-
eases and disorders (e.g. inflammatory bowel disease [5],
myocardial infarction [6], type-2 diabetes [7], schizo-
phrenic, schizotypal and delusional disorders [8] burn
injured adults [9], anxiety disorders [10]). However, in
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patients with somatoform disorders evidence of these
properties is still missing. The diagnostic category “somato-
form disorders” is used in both, ICD-10 [11] and DSM-IV
[12] classification systems. It includes several disorders
where a high number of medically unexplained symptoms
is the main feature, for which adequate somatic examin-
ation does not reveal sufficient explanatory pathology.
Referring to the prevalence rate, somatoform disorders are
common. It can be assumed that 15% to 20% of patients in
primary care suffer from a somatoform disorder [13-15].
The purpose of this study was to analyse the psychomet-
ric properties of the EQ-5D in patients with somatoform
disorders. More precisely, we focused on discriminative
ability (Does the instrument discriminate between different
states of the disorder?), construct validity (Does the instru-
ment measure the underlying construct to an appropriate
extent?) in terms of convergent validity (Are the instru-
ment scores correlated to the scores of instruments theor-
etically related?) and responsiveness of the EQ-5D (Does
the instrument detect health state changes that occur over
time?).
Methods
Study design
The origin of the data in this study is a cluster randomised
controlled trial (CRCT) designed to evaluate a 3-month
disorder-specific group intervention for patients with
somatoform disorders conducted by their general practi-
tioner (GP) and a psychosomatic specialist together in the
GP’s office. It is called the “speciAL” trial (specific collab-
orative group intervention for patients with somatoform
disorders in generAL practice) (ISRCTN55280791) [16].
Patient recruitment
The study sample was recruited by 35 GPs located in
the Rhine-Neckar area of south Germany. Inclusion cri-
teria were: (1) persistent (≥6 months) bodily complaints
without sufficient somatic explanation after systematic
differential diagnostic work-up according to the assess-
ment of the specifically trained GP; (2) medically unex-
plained symptoms (MUS) as the main treatment issue.
Exclusion criteria were: age below 18 or above 70 years,
residing further than 20 miles away from the respective
practice; ongoing psychotherapy; substance abuse; severe
psychiatric disorder (major depression, psychosis, de-
mentia, etc.); severe organic disease (operationalized by
Karnofsky index <70% [17]); being unable to complete
the questionnaire; ongoing medico-legal proceedings
due to disability pension or compensation for personal
suffering. After consenting, patients were given a screen-
ing questionnaire to determine study eligibility. There-
fore, the GPs’ patient recruitment had to be validated by
a positive score on at least one of two somatization
screeners: (1) At least mild somatic symptom severity on
the Patient Health Questionnaire (PHQ-15) represented
by a cutpoint of 5 [18] and/ or (2) relevant health anx-
iety on the Whiteley-7 (WI-7) [19]. Consistent with
Christensen et al. [20], the 5-point Likert scale of the
WI-7 was dichotomized (0=not at all/ a little, 1=moder-
ately/ quite a bit/ extremely) for screening purposes. A
sum score of ≥4 was used as indicative of relevant health
anxiety [21,22]. Eligible patients were sent the complete
baseline questionnaire. The recruitment of patients was
conducted between November 2007 and December
2009. 304 patients were included in the analysis of the
CRCT. Data were collected at baseline (t0), six months
after baseline (3 months after intervention) (t1) and 12
months after baseline (9 months after intervention) (t2).
Design and results of this trial have been reported else-
where [23]. The analysis presented in this article is based
on a sample of 294 patients. The difference follows from
EQ-5D questionnaires not returned from patients. Since
this study is a validation study, it is neither reasonable
nor necessary to separate the study sample into an inter-
vention and a control group nor to evaluate the groups
for imbalances.
Measures
EQ-5D: The EQ-5D is composed of five items concern-
ing `mobility´ (problems in walking about), `self-care´
(problems with washing or dressing), `usual activities´
(problems with performing usual activities – e.g. work,
study, housework, family or leisure activities), `pain/dis-
comfort´ and `anxiety/depression´ [24]. The response
options are located on a three level ordinal scale des-
cribing `1 – no problems´, `2 – moderate problems´
and `3 – severe problems´. This layout is called the EQ-
5D descriptive system. The result of the descriptive sys-
tem is called the EQ-5D self-reported health state, a five-
digit code specifying a specific health state (e.g. 11223 =
no problems in `mobility´, no problems in `self-care´,
moderate problems in `usual activities´, moderate pro-
blems in `pain/ discomfort´, severe problems in `anx-
iety/ depression´). Theoretically, 243 (35) different health
states can be defined by the EQ-5D descriptive system.
It is possible to assign an index score of quality of life to
each self-reported health state. The mentioned index
scores are based on a survey of the general population
in which participants were ask to assign utilities to dif-
ferent self-reported health states. Thus the EQ-5D index
represents the valuation of the patient’s health state from
a general population’s perspective (full health = 1.0). The
index scores employed in this study are based on a Brit-
ish tariff developed by Dolan et al. (EQ-5D index UK)
[25] and -alternatively- a German tariff developed by
Greiner et al. (EQ-5D index D) [26]. In addition to the
descriptive system, the EQ-5D includes a visual analogue
scale (EQ VAS). The EQ VAS is a rating scale ranging
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from 0 (worst imaginable health state) to 100 (best im-
aginable health state) and represents the valuation of the
health state from the patient’s point of view. The re-
spondent is asked to mark his actual health state on this
scale. The validated German version of the EQ-5D was
used in this study [26].
Patient Health Questionnaire 15 (PHQ-15)
The PHQ-15 is a subscale of the full PHQ and is applied
for the assessment of somatic symptom severity [27,28].
In patients with somatoform disorders the questionnaire
features a high internal reliability and convergent as well
as divergent validity [28]. It consists of 15 items covering
the most frequent symptoms in somatoform disorders
due to DSM-IV [28].
The scores of all 15 items can be accumulated to an
overall score between 0 and 30. A score between 0 and 4
represents a minimal somatic symptom severity, a score
between 5 and 9 a low, between 10 and 14 a medium
and scores greater than or equal to 15 a high somatic
symptom severity [28]. The validated German version of
the PHQ-15 was used in the present study [29].
Patient Health Questionnaire 9 (PHQ-9)
The PHQ-9 is a subscale of the full PHQ and is applied
for the assessment of depression severity [30]. The PHQ-9
has not been validated in a population of patients suffering
from somatoform disorders. However, because of its docu-
mented general usability in the assessment of depression,
we employed this questionnaire [30]. It contains 9 items,
checking the DSM-IV symptoms of depression. The over-
all score of the PHQ-9 ranges from 0 to 27. Depression se-
verity is classified as minimal (score 0 to 4), mild (5 to 9),
moderate (10 to 14), moderately severe (15 to 19) or se-
vere (20 to 27) [30]. The validated German version of the
PHQ-9 was used in the present study [31].
Whiteley Index 7 (WI-7)
The WI-7 is a screening instrument for illness worries
representing a cognitive/ emotional approach [19]. The
WI-7 was derived from the original Whiteley-Index
[19,32] and has acceptable psychometric properties in
patients with somatoform disorders [19]. It contains
seven questions relating to worries about health, body,
symptoms, illness or accuracy of diagnosis. The response
options for the questions are displayed on a 5-point
Likert scale. The WI-7 overall score ranges from 0 to 28.
Higher scores are indicating more severe disease states.
The validated German version of the WI-7 was used in
this study [33,34].
Short Form 36 (SF-36)
The SF-36 is a health related quality of life questionnaire
consisting of 36 items which compose 8 health concepts
forming a health profile [35,36]. These health concepts
are physical functioning (PF), physical role functioning
(RP), bodily pain (BP) and general health perceptions
(GH) as well as vitality (VT), social functioning (SF), emo-
tional role functioning (RE) and mental health (MH). The
dimensional scores reach values from 0 (worst health
state) to 100 (best health state). Furthermore, two compo-
nent scores – physical (PCS) and mental (MCS) – can be
calculated by summarizing the weighted dimensional
scores. The German standard version of the SF-36 was
used in the present study [37]. Although not formally vali-
dated in patients with somatoform disorders, the SF-36
has been frequently used in this population [38-41].
Psychometric analyses
Discriminative ability refers to the ability of a measure to
distinguish between different health states [42]. We
hypothesised that the EQ-5D is able to distinguish between
patients with somatoform disorders and the general popu-
lation and to differentiate between patients with different
severities of illness. For the comparison with the general
population data from a representative survey (n = 3552)
using the EQ-5D in the German general population in
2002/2003 were available [43].
To evaluate the discriminative ability between patients
with different severities of disease the relationship of the
EQ-5D descriptive system, the EQ VAS and the EQ-5D
index scores to the somatic symptom severity was ana-
lysed. We chose the PHQ-15 as it depicts the severity of
somatoform disorders. To assess the EQ VAS score and
the score of the British and German EQ-5D index for
ceiling effects, the distribution of these scores was ana-
lysed by percentiles and by the proportion of patients
achieving the highest possible scores.
Construct validity applies to the ability of an instrument
to reproduce the underlying construct in a reasonable
manner [44]. We analysed only a part of construct validity,
namely convergent validity. This means we focussed on
the correlation of the EQ-5D with instruments which are
based on related theoretical constructs [42]. We hypothe-
sised that there is an association between the EQ-5D and
measurements of psychopathology, symptoms and quality
of life on the item level, the level of the EQ VAS and the
level of the EQ-5D index scores. The reference instru-
ments in the evaluation of the EQ-5D were the PHQ-15,
PHQ-9, WI-7 and the SF-36.
Responsiveness refers to the capability of an instrument
to detect changes of the health state over time [45]. We
hypothesised that the EQ-5D is responsive. We used the
disease specific PHQ-15 to analyse the responsiveness of
the EQ-5D and furthermore employed the health transi-
tion question of the generic SF-36 as a measure of
change to perform the analysis from a generic perspec-
tive as well. The health transition question does not
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contribute to any of the eight health concepts or of the
two component scores of the SF-36 [46]. The transition
question is a 5-point Likert scale ranging from `much´
and `somewhat better´ over `about the same´ to `some-
what´ and `much worse´, which reports the actual health
state in comparison to the health state one year ago. In
line with this analysis, the responses “much” or “somewhat
better” and “much” or “somewhat worse” are summarised
as “better” and “worse” health respectively. “About the
same” is labelled as “same” or “unchanged” health.
Statistical methods
Concerning the statistical methods, two facts have to be
highlighted. First, the categories `moderate problems´
and `severe problems´ of the EQ-5D descriptive system
were pooled into one category `problems´, as `severe
problems´ occurred rarely. Therefore, for all analyses of
convergent validity on item level, the items of the EQ-
5D descriptive system were used as dichotomous vari-
ables (no problems; problems). Second, as the EQ VAS
and both EQ-5D index scores showed no normal distri-
bution, non-parametric methods were employed. No ad-
justment for clustering of patients around GPs was
performed, as all observed ICCs for baseline values were
smaller than 0.1, indicating a low level of relatedness of
patient characteristics within the clusters [23].
To assess discriminative ability, the χ2-test (EQ-5D
items) and the Kruskal-Wallis test (EQ VAS and EQ-5D
index scores) were used. The analysis of the discrimina-
tive ability was based on the baseline data.
Because of the different nature of the data of the EQ-
5D descriptive system on the one hand and of the EQ-
5D index scores and the EQ VAS on the other hand we
had to choose different statistical approaches in the
evaluation of convergent validity. The Mann–Whitney
test was applied and the effect size (Cohen’s d) was cal-
culated for assessing the EQ-5D descriptive system. The
Spearman rank correlation coefficient (rs) was calculated
for assessing the EQ VAS and the EQ-5D index scores.
According to Cohen, a correlation was considered small
for 0.1 ≤ |rs| < 0.3, moderate for 0.3 ≤ |rs| < 0.5 and
large for |rs| ≥ 0.5 [47]. The analysis of the convergent
validity was based on the baseline data. In order to iden-
tify not only the hypothesized correlations and effects
but also those unexpected, we performed a complete
analysis for the items of the EQ-5D, the EQ-5D index
scores and the EQ VAS.
Responsiveness was evaluated measuring the mean dif-
ferences, effect sizes (ES) and standardised response
means (SRM) in the groups of patients reporting worse,
same and better health on the SF-36 transition question,
and by the Spearman rank correlation coefficient (rs) of
the changes scores of the PHQ-15 and the EQ-5D. ES
was calculated as follows: ES = (Mx – M0)/ SDBaseline.
M0 denotes the mean score of the baseline assessment,
Mx the mean score of the follow-up assessment at time x.
SDBaseline is the standard deviation of the baseline assess-
ment. SRM was defined as: SRM = (Mx – M0) / SDMX –
M0. The numerator is the same as in case of the ES, the
denominator is the standard deviation of the difference in
scores. Scores of ES and SRM ≥ |0.8| were considered as
large effect, scores from ≥ |0.5| to < |0.8| as medium,
scores from ≥ |0.2| to < |0.5| as small and scores ≥ |0.1| to
|0.2| as trivial [47]. As we employed the transition ques-
tion of the SF-36 which covers the change in health com-
pared to one year before, the evaluation of responsiveness
focussed on the period between t0 and t2.
For statistical testing, the level of significance was
defined at α = 0.05. Since several hypotheses are tested
per item and score of the EQ-5D, the Bonferroni correc-
tion was performed. As 13 different scores were used for
assessing the convergent validity of the EQ-5D, the level
of significance was defined at α = 0.05 / 13 = 0.0038.
Analyses were performed using the Statistical Package
for the Social Sciences (version 18.0, SPSS Inc., Chicago,
IL, USA).
Results
Sociodemographic characteristics
The baseline sociodemographic characteristics of the
294 analysed patients are displayed in Table 1. The mean
age of the analysed sample was 49.06 years (SD: 12.51).
The majority of participants was female (74.9%), married
or living with a partner (69.8%) and possessing a second-
ary school graduation (73.2%).
Descriptive statistics of the EQ-5D
86.7% of patients reported problems in the item `pain/
discomfort´, 66.3% in the item `anxiety/ depression´, fol-
lowed by `usual activities´ (47.4%), `mobility´ (28.6%)
and `self-care´ (3.1%). Only 6.8% of patients reported no
problems at all (Table 2). The most frequently reported
health state was 11122, which indicates moderate pro-
blems in the items `pain/ discomfort´ and `anxiety/ de-
pression´. Health states with more than one scaling of
`severe problems (3) were hardly reported. The distribu-
tions of the EQ VAS and the EQ-5D index scores are
displayed in Table 3. The mean EQ VAS score was 58.56
(SD: 19.99) (0 to 100 = worst to best imaginable health
state). The mean scores of the EQ-5D index UK and the
EQ-5D index D were 0.62 (SD: 0.27) and 0.77 (SD: 0.24)
respectively (full health = 1.0).
Scores of reference instruments
The scores of the reference instruments are presented in
Table 3. The mean score of the PHQ-15 was 12.66 (SD:
4.81) representing a medium severity of somatoform dis-
order. 84 patients (29%) suffered from a minimal or low
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(PHQ-15: 0–9), 110 patients (37%) from a medium
(PHQ-15: 10–14) and 100 patients (34%) from a high
somatic symptom severity (PHQ-15: 15–30). The PHQ-9
showed a mean score of 9.33 (SD: 5.35) describing mild
to moderate severity of depression. The WI-7 displayed
a mean of 10.91 (SD: 6.54). The mean scores for the SF-
36 health concepts PF, RP, SF and RE were located be-
tween 60 and 70, for the health concepts BP, GH and
MH around 50 and the score for VT nearly 40. The
values of the PCS and the MCS were around 40.
Discriminative ability
Figure 1 shows the discriminative ability of the EQ-5D
in terms of the differences between the study population
and a general population sample from Germany (n =
3552) [43]. The study population of patients with soma-
toform disorders reported significantly more problems
in four of five items of the EQ-5D (p < 0.001). Only in
the item `self-care´, there was no difference apparent.
The maximum score of the EQ VAS, the EQ-5D index
UK and the EQ-5D index D was reached by only 1%,
6.8% and 12.6% of patients with somatoform disorders
(data not shown). Considering the percentiles of the dis-
tribution of the EQ-5D scores, there was no distinct ceil-
ing effect for the EQ VAS and the EQ-5D index UK but
for the EQ-5D index D (data not shown).
The ability of the EQ-5D to discriminate between dif-
ferent somatic symptom severities is presented in
Table 4. In every item of the EQ-5D descriptive system
the proportion of patients with problems in the particu-
lar grade of somatic symptom severity increased with
the increase of somatic symptom severity. Furthermore,
the valuation of the health state decreased with the in-
crease of somatic symptom severity. For the EQ-5D de-
scriptive system, the EQ VAS and the EQ-5D index
scores the differences in proportions and scores were
significant.
Convergent validity
Table 5 shows the associations between the response
level of the EQ-5D items and the scores of the reference
instruments. Displayed are the mean scores of the refer-
ence instruments categorized by the presentation of pro-
blems according to the EQ-5D items. Furthermore,
effect sizes (Cohen’s d) are reported.
For nearly all reference instruments, significant differ-
ences in mean scores between respondents with and with-
out problems in the various EQ-5D items were found.
The following results should be emphasised (p < 0.001)
as they indicate convergent validity:
(1) Patients with moderate or severe problems in
`mobility´ reported worse HRQOL in the SF-36
health concept `physical functioning´ than patients
without problems. This difference represented an
effect size of 1.7.
(2) Patients with moderate or severe problems in `pain/
discomfort´ reported worse HRQOL in the SF-36
health concept `bodily pain´ than patients without
Table 1 Sociodemographic characteristics of the study
sample (n = 294)
Age in years
mean (SD) 49.06 (12.51)
median 49
Gender
male 25.2%
female 74.8%
Martial statusa
unmarried 20.0%
married 65.6%
separated/ divorced 10.3%
widowed 4.1%
Living arrangementb
living alone 22.3%
living with spouse/ partner 70.0%
living withe parents/ relatives 4.9%
other 2.8%
Educationc
no school graduation 1.4%
secondary school graduation 73.1%
technical college/ university entrance qualification 13.3%
college/ university degree 11.9%
other (e.g. school for mentally handicapped children) 0.3%
a 4 missing values of this variable (n= 290).
b 7 missing values of this variable (n = 287).
c 8 missing values of this variable (n = 286).
Table 2 EQ-5D descriptive system: most frequently
reported EQ-5D self-classified health states
EQ-5D health state (regarding five items in the
following order: `mobility´, `self-care´, `usual activities´,
`pain/ discomfort´,`anxiety/ depression´
n (%)
11122* 57 (19.5%)
11222 42 (14.2%)
11121 41 (13.9%)
21222 25 (8.5%)
11111 20 (6.8%)
11112 16 (5.4%)
21221 13 (4.4%)
11221 9 (3.1%)
21232 8 (2.7%)
11223 7 (2.4%)
This table lists all health states which were reported at least five times among
all respondents. Hence percentages do not sum up to 100%. There was one
missing value for the EQ-5D self-classified health state (n=294). *1 – no
problems, 2 – moderate problems, 3 – severe problems.
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problems. This difference represented an effect size
of 1.50.
(3) Patients with problems in `anxiety/ depression´
reported worse HRQOL in the SF-36 MCS and its
health concepts (VT, SF, RE, MH) as well as worse
scores in the PHQ-9 than patients without
problems. All differences represented large effect
sizes.
(4) Patients with problems in `mobility´, `self-care´,
`usual activity´ and `pain/ discomfort´ reported
worse HRQOL in the SF-36 PCS and most of its
health concepts (PF, RP, BP, GH) than patients
without problems. All differences represented large
effect sizes.
The PHQ-15 and the WI-7, measuring somatoform
complaints from a symptom perspective and with a cog-
nitive/ emotional approach, respectively, showed signifi-
cant differences, but only moderate effect sizes. The only
exception was the item `self-care´. For this item large ef-
fect sizes were observed.
The evaluation of the EQ VAS and the EQ-5D index
scores lead to similar results (Table 6): All correlations
with the other measures were highly significant; most
correlations between the reference instruments and the
EQ VAS and the EQ-5D index UK were large. Excep-
tions were the PHQ-15, PHQ-9 and WI-7, showing only
moderate correlations with the EQ VAS and the EQ-5D
index scores, as well as the SF-36 MCS and the health
concepts `mental health´, `role physical´ and `role
emotional´. The EQ-5D index D showed moderate cor-
relations mostly. Strong correlations were found with
the PCS and the concepts `physical functioning´ and
`bodily pain´ of the SF-36. The correlations between the
EQ-5D index D on the one hand and the MCS and the
concept `role emotional´ of the SF-36 on the other hand
were only small.
Responsiveness
Table 7 shows the responsiveness statistics. Anchored by
the SF-36 transition question the EQ VAS and the EQ-
5D index scores showed some effects after one year (be-
tween t0 and t2), especially in the group of patients
reporting improved health. In this group the effect on
the EQ VAS was medium, while the effect on the EQ-5D
index scores was small. As expected there were only
trivial effects in the group of patients reporting un-
changed health. In the group of patients reporting worse
health the effect on the VAS was trivial, while the effect
on the EQ-5D index scores was small. The analysis by
means of the disease specific PHQ-15 showed similar
results (data not shown). We found highly significant,
but only moderate correlations between changes in the
PHQ-15 score and changes in the EQ VAS score (rs =
−0.311, p < 0.000) and significant small correlations be-
tween changes in the PHQ-15 score and changes in the
EQ-5D index UK (rs = −0.167, p = 0.011). The small cor-
relation of the PHQ-15 and the EQ-5D index D (rs =
−0.144, ns) was not significant.
Table 3 Scores of instruments
Measures Range: worst - best n Score
Mean (SD) Median (range)
Health-related quality of life EQ VAS (0 – 100) 287 58.56 (19.99) 60 (0–100)
EQ-5D index UK (−0.594 – 1.00) 293 0.62 (0.27) 0.73 (−0.18 – 1.00)
EQ-5D index D (−0.2 – 1.00) 293 0.77 (0.24) 0.89 (0.11 – 1.00)
SF-36
Physical component score (PCS) (2–76) 294 42.78 (9.11) 42.96 (13.99-65.40)
Mental component score (MCS) (1–81) 294 40.86 (10.61) 40.61 (14.15-64.66)
Physical functioning (PF) (0–100) 294 70.86 (24.10) 75 (0–100)
Role physical (RP) (0–100) 294 68.62 (26.36) 75 (0–100)
Bodily pain (BP) (0–100) 294 48.50 (25.54) 41 (0–100)
General health (GH) (0–100) 294 49.75 (18.54) 50 (5–100)
Vitality (VT) (0–100) 294 39.75 (20.33) 40 (0–100)
Social functioning (SF) (0–100) 294 61.97 (28.08) 62.50 (0–100)
Role emotional (RE) (0–100) 294 67.58 (27.22) 66.67 (0–100)
Mental health (MH) (0–100) 294 54.71 (19.68) 56 (8–100)
Symptoms PHQ-15 Sum score (30–1) 294 12.66 (4.81) 12 (2–26)
PHQ-9 Sum score (27–0) 294 9.33 (5.35) 9 (0–27)
Illness worries WI-7 Sum score (28–0) 294 10.91 (6.54) 10 (0–28)
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Discussion
To our knowledge, this study is the first to evaluate the
psychometric properties of the EQ-5D in patients with
somatoform disorders.
Discriminative ability
The EQ-5D proved discriminative ability in somato-
form disorders: It showed significant differences be-
tween patients with somatoform disorders and the
general population. Large differences were especially
found for the items `pain/ discomfort´ and `anxiety/
depression´. The only item showing no differences in
comparison to the general population was `self-care´.
For the EQ-5D self-reported health state no ceiling or
floor effects were identifiable, as on the one side just
6.8% of patients reported a health state of 11111 with-
out any problems, and on the other side health states
with severe problems in more than one dimension were
rarely reported. The same applies to the EQ VAS and
the EQ-5D index UK. The EQ-5D index D showed a
distinct ceiling effect. This effect results from the de-
velopment of the German EQ-5D index. It was esti-
mated based on a rather small general population
sample of N = 334 and the 243 health states of the EQ-
5D were derived from a set of 36 health states using a
regression model. For this reason the EQ-5D index D
has to be considered as less precise and preliminary.
The consequence of this is that the health state 11112,
i.e. no problems but moderate problems in the dimen-
sion anxiety / depression, is not connected with a loss
of health related quality of life.
Furthermore, the results concerning the discriminative
ability support the assumption that the EQ-5D items,
the EQ VAS and the EQ-5D index scores are able to dif-
ferentiate between patients with different severities of
somatoform disorders.
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Figure 1 Distribution of responses to items of EQ-5D descriptive system in patient sample (n = 295) and general population (n = 3552) [43].
Brettschneider et al. Health and Quality of Life Outcomes 2013, 11:3 Page 7 of 12
http://www.hqlo.com/content/11/1/3
Convergent validity
Especially three items of the EQ-5D descriptive system
were strongly associated with a generic reference instru-
ment and thereby indicated convergent validity: Strong
associations were found (1) between the EQ-5D item
`anxiety/depression´ and the PHQ-9 as well as the SF-
36/ MCS and its health concepts, (2) between the EQ-
5D item `pain/discomfort´ and the SF-36 health concept
`bodily pain´, and (3) between the EQ-5D item `mobil-
ity´ and the SF-36 health concept `physical functioning´.
The other two EQ-5D items `usual activities´ and `self
care´ definitely emphasise the physical health state, but
also seem to be affected by the mental component
[8,48]. Under this assumption the results confirm the
presence of convergent validity for the EQ-5D item
`usual activities´, as it showed associations with six of
the eight SF-36 health concepts and with the PCS. Thus,
physical and mental health concepts seem to be repre-
sented by this item. For the item `self-care´ the same
cannot be stated, as it achieved large effect sizes only in
physical health concepts and no significant results in the
mental health concepts of the SF-36.
The associations between the EQ-5D items and the
disorder-specific instruments were significant but only
moderate in most instances. The evaluation of the EQ
VAS and the EQ-5D index scores provided similar
results. They correlated significantly with all dimensions
of the generic and the specific instruments, but strong
correlations, which were found mainly for the EQ VAS
and the EQ-5D index UK, occurred primarily with the
generic instruments.
This weak association with disorder-specific instru-
ments deviates from the results of other studies which
validated the EQ-5D in patients with mental disorders
like anxiety disorder or schizophrenic, schizotypal and
delusional disorders [8,10]. A possible explanation is that
the PHQ-15 and the WI-7 are symptom measures, and
their overall scores are symptom scores, whereas the
EQ-5D scores (VAS, Index UK and Index D) represent a
valuation of the health state. Additionally it has to be
kept in mind that the PHQ-15 and the WI-7 are psycho-
metric instruments describing a health state partially,
whereas the EQ-5D scores are preference-based mea-
sures valuing the utility of a health state. As the reci-
procity between psychometrically measured symptom
status and preference-valued health status is not clear, it
cannot be stated definitively whether and how the pres-
ence of individual symptoms is reflected in the valuation
of a specific health state. It can be hypothesised that
both constructs are not connected closely enough to
show large correlations in this analysis.
Finally, it is worth mentioning, that there is no strong
correlation between the EQ VAS or the EQ-5D index
scores and the MCS. This could be explained by the na-
ture of the EQ-5D, which consists of four items (`pain/
discomfort´, `mobility´, `self-care´, `usual activities´)
Table 4 Association between somatic symptom severity (PHQ-15) and EQ-5D
Number of patients with problems in EQ-5D item: EQ VAS Score EQ-5D Index UK EQ-5D Index D
Somatic
symptom
severity
(PHQ-15)
Mobility
(%) a
Self-care
(%) a
Usual
Activity (%) a
Pain/
Discomfort
(%) a
Anxiety/
Depression
(%) a
Mean
(SD)
Median Mean (SD) Median Mean (SD) Median
●
Minimal/
Low
14
(16.6%)
0 (0.00%) 22 (26.2%) 65 (77.4%) 44 (52.4%) 68.59
(18.75)
70 0.75 (0.16) 0.727 0.87 (0.14) 0.888
(0–9)
(n=84 /
29%)
●
Medium
32
(29.1%)
2 (1.80%) 54 (51.8%) 96 (87.3%) 72 (65.5%) 58.8
(18.54)
60 0.65 (0.24) 0.691 0.80 (0.2) 0.888
(10–14)
(n=110 /
37%)
● High 38
(38.0%)
7 (7.00%) 63 (63.0%) 94 (94.0%) 79 (79.0%) 50.01
(18.72)
50 0.49 (0.32) 0.689 0.66 (0.3) 0.838
(15–30)
(n=100 /
34%)
p-value 0.006b 0.009b < 0.001b 0.004b 0.001b < 0.001c < 0.001c < 0.001c
a Proportion of patients with problems according to the EQ-5D item in the group of patients with low / medium / high disease severity b Chi-square test;
c Kruskal-Wallis test; This analysis is based on baseline data.
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Table 5 Association between response level of EQ-5D items and score of other measures
Other measures Mean score of other measures by response level of EQ-5D item
EQ-5D item Mobility Self Care Usual Activity Pain/ Discomfort Anxiety/ Depression
Problems: No Yes da No Yes da No Yes da No Yes da No Yes da
Symptoms PHQ-15
● Sum score 11.99 14.4 −0.51** 12.54 17.00 −1.13* 11.3 14.23 −0.64** 9.56 13.15 −0.78** 11.17 13.44 −0.20**
PHQ-9
● Sum score 8.68 10.95 −0.43** 9.21 12.89 −0.61 7.57 11.29 −0.73** 7.18 9.65 −0.49 6.37 10.83 −0.94**
Illness worries WI-7
● Sum score 9.93 13.27 −0.52** 10.68 17.44 −1.14 8.83 13.08 −0.69** 7.92 11.34 −0.55* 8.34 12.17 −0.64**
Health-related quality of life SF-36
● Physical component score 45.76 34.18 1.61** 42.85 29.89 1.92** 46.44 38.13 1.04** 52.15 40.96 1.50** 43.05 42.14 0.10
● Mental component score 41.20 40.56 0.06 41.14 37.37 0.32 44.81 36.72 0.81** 43.81 40.59 0.30 49.00 36.97 1.32**
Physical functioning 80.14 46.84 1.70** 71.71 36.36 1.69** 81.22 59.25 1.03** 90.58 67.57 1.23** 75.02 68.39 0.28
Role physical 71.79 56.55 0.55** 68.51 33.33 1.23** 77.60 55.94 0.86** 84.62 64.80 0.87** 75.76 63.21 0.49**
Bodily pain 54.66 29.52 1.24** 48.32 20.78 1.46** 57.53 36.53 0.94** 76.92 42.98 1.45** 52.38 44.99 0.30
General health perceptions 53.06 41.10 0.72** 50.06 36.33 0.77 56.85 41.83 0.90** 63.92 47.45 0.95** 55.71 46.56 0.51**
Vitality 43.14 30.40 0.67** 39.97 24.63 0.75 48.94 28.85 1.17** 53.12 37.42 0.78** 50-57 33.88 0.90**
Social functioning 65.95 52.23 0.50** 62.50 47.22 0.53 75.57 47.93 1.17** 74.68 60.10 0.53* 78.41 53.72 0.97**
Role emotional 69.84 61.51 0.29 68.19 44.44 0.73 76.19 57.55 0.70** 79.49 65.62 0.53* 83.84 59.15 1.01**
Mental health 56.50 50.94 0.27 55.27 43.56 0.55 61.82 47.22 0.79** 62.77 53.71 0.48 68.29 48.12 1.17**
There were missing values for some of the other measures used for comparison; the number of observations is presented in Table 3; p-values for differences in scores: * p < 0.003; ** p < 0.001; a |d| = effect size
(Cohen´s d), large effect sizes (|d| ≥ 0.8) are printed bold. This analysis is based on baseline data.
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that emphasise physical health primarily, and only one
item (`anxiety/ depression´) focusing on mental health.
Nevertheless, this is a problem that reduces the conver-
gent validity of the EQ VAS and the EQ-5D index scores
by a certain degree, as somatoform disorders are psycho-
somatic disorders after all, even though they become
manifest in somatic symptoms.
Responsiveness
For the assessment of responsiveness the use of the dis-
ease specific PHQ-15 as an anchor of change would be
the method of choice. As there is no minimal important
difference reported in the literature we chose the transi-
tion question of the SF-36 as an anchor. However, tran-
sition questions are considered as being biased [49]. For
this reason we additionally employed a correlation ana-
lysis based on the PHQ-15 to support our findings. With
respect to the responsiveness, it can be stated that the
EQ-5D is responsive to a limited degree. In the group of
patients with improved health on the transition question
of the SF-36, the EQ VAS score and the EQ-5D index
scores were responsive between t0 und t2. In the group
of patients without changes in health, the EQ VAS score
and the EQ-5D index scores showed no effect, which is
Table 6 Correlation between EQ VAS score, EQ-5D index and scores of other measures
Other measures Correlation EQ VAS
score
Correlation EQ-5D index
UK
Correlation EQ-5D index
D
Symptoms PHQ-15
● Sum score −0.468 −0.448** −0.392**
PHQ-9
● Sum score −0.489 −0.474** −0.345**
Illness worries WI-7
● Sum score −0.471 −0.431** −0.331**
Health-related quality of
life
SF-36
● Physical component score 0.589 0.574** 0.636**
● Mental component score 0.470 0.441** 0.221**
Physical functioning 0.538 0.567** 0.600**
Role physical 0.423 0.467** 0.386**
Bodily pain 0.599 0.579** 0.595**
General health
perceptions
0.633 0.509** 0.464**
Vitality 0.586 0.555** 0.412**
Social functioning 0.564 0.530** 0.381**
Role emotional 0.382 0.436** 0.254**
Mental health 0.517 0.477** 0.308**
Large correlations (|rs| ≥ 0.5) are printed bold;
* p < 0.0038; ** p < 0.001; the number of observations used for the calculation was 286 ≤ n ≤ 293, subject to
missing values; the correlation of the EQ VAS score with the EQ-5D index UK was |rs| = 0.669 (p < 0.001); the correlation of the EQ-VAS with the EQ-5D index-D
was |rs| = 0.635 (p < 0.001); the correlation of the EQ-5D index UK with the EQ-5D index D was 0.886 (p < 0.001). This analysis is based on baseline data.
Table 7 Responsiveness of EQ VAS, EQ-5D index UK and EQ-5D index D based on SF-36 transition question as an
external anchor of change
Statistics Score Change of health state anchored by SF-36 transition question
Worse (n=64) Same (n=72) Better (n=91)
t0 – t2 Mean difference (SD) EQ VAS −3.386 (19.714) −3.284 (17.420) 10.744** (16.755)
EQ-5D index UK −0.065 (0.285) 0.029 (0.249) 0.076** (0.199)
EQ-5D index D −0.069 (0.266) 0.018 (0.229) 0.046* (0.181)
Effect size EQ VAS −0.17 −0.14 0.62
EQ-5D index UK −0.18 0.11 0.39
EQ-5D index D −0.22 0.08 0.26
Standardised response mean EQ VAS −0.16 −0.15 0.65
EQ-5D index UK −0.20 0.12 0.38
EQ-5D index D −0.23 0.07 0.25
Significant t-statistics (*p < 0.05; **p < 0.001) are printed bold.
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desirable. In patients reporting worse health neither the
EQ VAS nor the EQ-5D index scores was responsive.
From the disease specific perspective of the analysis only
the EQ VAS showed a moderate correlation to changes
measured by the PHQ-15.
Limitations
The main limitation of this study results from the study
population. Only patients with persistent medically unex-
plained symptoms (MUS) were included in the study. This
could limit the generalisability of the results. However, ir-
respective of the chronic courses of illness, the distribution
of somatic symptom severity in the study population was
well-balanced (Table 4). So even if an influence of the
selected patient sample on the generalisability of the study
has to be supposed, the principle of this study is not
affected.
Conclusions
The EQ-5D discriminated between patients with somato-
form disorders and the general population, as well as
between different severity states of somatoform disorders.
The convergent validity of the EQ-5D items, the EQ VAS
and the EQ-5D index scores was demonstrated. The EQ-
5D items as well as the EQ VAS and the EQ-5D index UK
show considerable associations with other measures of the
constructs in question. The convergent validity of the EQ-
5D index D is less pronounced yet present. The respon-
siveness of the EQ-5D index scores was limited; it was
only significant for patients reporting an improved health
state. In summary, the EQ-5D possesses a considerable
validity and a limited responsiveness in patients with
somatoform disorders.
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